Aurinia Pharmaceuticals (AUPH) Intangibles (2016 - 2026)

Aurinia Pharmaceuticals has reported Intangibles for 11 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 13.66% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (down 13.66% YoY), and the FY2025 full-year result was $3.8 million, down 13.64% from the prior year.
• Intangibles for Q1 2026 stood at $3.6 million, down from $3.8 million in the prior quarter.
• The five-year high for Intangibles was $7.9 million in Q1 2022, with the low at $3.6 million in Q1 2026.
• Historically, Intangibles has averaged $5.2 million across 5 years, with a median of $4.8 million in 2024.
• Annual changes were most pronounced in 2022 — Intangibles fell 23.55% — and 2025, when it fell 12.44%.
• Aurinia Pharmaceuticals' Intangibles stood at $6.4 million in 2022, then retreated by 22.54% to $5.0 million in 2023, then retreated by 12.5% to $4.4 million in 2024, then retreated by 13.64% to $3.8 million in 2025, then decreased by 4.55% to $3.6 million in 2026.
• The last three Intangibles figures came in at $3.6 million (Q1 2026), $3.8 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.